Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA

Sun Pharmaceutical Industries — Ranbaxy Laboratories — FY2014 Earnings Presentation

17 slides from Sun Pharmaceutical Industries's earnings presentation, May 9, 2014

  1. Slide 1: Financial Results: January – March 2014 (FY2014)

    Ranbaxy Laboratories Limited FINANCIAL RESULTS: January – March 2014 (Jan- Mar 14) 15 month period ended March 2014 (FY2014) ARUN SAWHNEY CEO & MD Dept. 09 May Name 2014 Post Results Conference Call

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p

  3. Slide 3: Key Achievements for Jan-Mar 14

    1/3 Key Achievements for Jan- Mar 14 Financial  Sales seem lower primarily due to the impact of halt in API shipments 24,112 24,361 6% Percent 6% Rs. Mn Jan- Mar 13 Jan- Mar 14 Jan- Mar 13 Jan- Mar 14 Sales EBITDA/ Sales % Growth calculated on Constant Forex 3

  4. Slide 4: Key Achievements for months ended Mar 2014

    2/3 Key Achievements for 15 months ended Mar 2014 Financial  Achieved sales guidance with Rs.130.4 Bn sales for the 15 month period ended Mar 2014  Base business sales and EBITDA continued to grow 130,403 7% Percent Rs. Mn FY2014 FY2014 Sales EBITDA/ Sales % Growth calculated on Constant Forex Cur

  5. Slide 5: Highlights: Quarter and months ended Mar 2014 Business

    3/3 Highlights: Quarter and 15 months ended Mar 2014 Business  Branded category sales Rs.13,178 Mn for Q5; Rs.63,965 Mn for FY14  54% of sales for Q5  Generic including API sales Rs.11,184 Mn for Q5; Rs.66,438 Mn for FY14  46% of sales for Q5  India:  Domestic business continued to grow  USA:

  6. Slide 6: Other Areas: R&D, Regulatory, Derivatives Position, Debt

    Other Areas Research & Development and Regulatory  DF filings: 37; DF approvals:22  Consent Decree progressed as per plan Derivatives Position  Exposure down to ~$568 Mn as on 31 Mar 2014 from ~$665 Mn in Q4 2013. Maturity: ~$33 Mn/month Debt  Debt $1,087 Mn; Cash & Bank $256 Mn  Net Debt $832

  7. Slide 7: Financial Performance

    Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: January – March 2014 (Jan- Mar14) 15 month period ended March 2014 (FY2014) Dept. Name

  8. Slide 8: Sales Performance

    Sales Performance Rs. Mn Consolidated Sales Jan- Mar 14 24,111 24,361 Consolidated Sales 15 months period ended March 2014 (7%) Rs.130,403 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Sales grew in the major markets of USA, India, West Europe and LATAM Growth calculated on Constant Forex Current accounting

  9. Slide 9: North America

    North America Rs. Mn Major markets -USA -Canada 8,434 6,605 13% Rs.42,003 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Strong base business growth  Absorica™ growth story continued during the Quarter Growth calculated on Constant Forex Current accounting year is of 15 months; not comparable with the previo

  10. Slide 10: India

    India Rs. Mn 5,427 5,536 2% Rs.27,930 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Performance in the IPM recovered  Primary sales grew over the corresponding quarter Growth calculated on Constant Forex Current accounting year is of 15 months; not comparable with the previous accounting year 10

  11. Slide 11: East Europe & CIS

    East Europe & CIS Rs. Mn Major markets -Romania -Russia -Ukraine 3,604 3,786 (4%) Rs.19,980 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Business performance in the region was adversely impacted by forex movement  Poland sales grew while Russia was impacted by low cold season Growth calculated on Constant

  12. Slide 12: West Europe

    West Europe Rs. Mn Major markets -France -Germany -UK 2,452 2,018 2% Rs.10,798 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Sales in the region was helped by strong performance in UK  Regional focus on profitability continued Growth calculated on Constant Forex Current accounting year is of 15 months; not

  13. Slide 13: Asia Pacific & Latin America

    Asia Pacific & Latin America Rs. Mn Major markets -ANZ -Malaysia 1,659 -Brazil 1,547 (13%) Rs.9,241 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Sales impacted due to change in business model in Thailand and loss of tenders in Malaysia  Sales grew in the important markets of Australia and Brazil Growth cal

  14. Slide 14: Africa & Middle East

    Africa & Middle East Rs. Mn Major markets -South Africa -Nigeria 2,983 2,049 (36%) Rs.12,966 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Sales impacted by the lower tender sales in the Quarter Growth calculated on Constant Forex Current accounting year is of 15 months; not comparable with the previous acco

  15. Slide 15: API & Others

    API & Others Rs. Mn 1,815 557 (73%) Rs.7,485 Mn Jan- Mar 13 Jan- Mar 14 15 mths  Sales impacted by voluntary halt of shipments from Dewas and Toansa Growth calculated on Constant Forex Current accounting year is of 15 months; not comparable with the previous accounting year 15

  16. Slide 16: Financials: Quarter and 15 months ended March 2014: INR

    Financials: Quarter and 15 month ended March 2014: INR Jan- Mar 2013 YTD Dec 2012 Particulars Jan- Mar 2014 15 mnths ended Mar 2014 3 months 12 months 3 months 15 months 5,611 22,008 -Within India 5,636 28,628 18,500 100,521 -Outside India 18,725 101,776 24,111 122,529 Sales 24,361 130,403 607 2,068

  17. Slide 17: Questions & Answers

    Questions & Answers Dept. Name

Ranbaxy Laboratories — FY2014 Earnings Presentation on 6ix